NASD · Healthcare · Biotechnology · USA
Altimmune Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.
Altimmune is a biopharmaceutical company developing pemvidutide, a glucagon/GLP-1 dual receptor agonist for treating liver diseases. The company is advancing pemvidutide in clinical trials for metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. Pemvidutide has demonstrated clinical benefits including liver fat reduction, weight loss, and improvements in liver inflammation markers.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Altimmune Inc stock.
Overvalued: intrinsic value $1.15 per share, market price $1.53, margin of safety -33.4% (as of 2026-11-17).
Its liquidation floor, current assets minus every liability, values the shares at $1.15; the price of $1.53 is 33% above that value.
17 more funds hold it; the full list is part of the paid plan.
36 more in this industry show a wider margin of safety.
ALT is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $1.15; the price of $1.53 is 33% above that value.
$1.15 per share (as of the 2026-11-17 close), against a market price of $1.53. That is a margin of safety of -33.4%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.